Tissue engineering. Mending the youngest hearts.
Tissue engineering. Mending the youngest hearts.
复制标题
DOI：
10.1126/science.333.6046.1088
复制
发表时间：
2011-08
期刊：
影响因子：
56.9
通讯作者：
G. Vogel
中科院分区：
文献类型：
--
作者：
G. Vogel
组织工程本月，经过艰难的批准程序，外科医生正在美国第一批患者身上测试组织工程心脏血管。植入物，用于连接主要的心脏静脉和动脉，将血液输送到肺部，是由一个人工合成的支架制成，植入了来自患者自己骨髓的细胞。在体内，移植物发育成与患者一起生长的活血管。但新的实验表明，炎症，长期以来被视为移植和人工植入物的敌人，似乎在细胞填充的支架转化为健康血管的过程中发挥了关键作用。而被视为组织工程之星的干细胞，其作用也没有预期的那么重要。这些结果促使组织工程师重新思考炎症和干细胞的作用。
Tissue EngineeringThis month, after an arduous approval process, surgeons are testing tissue-engineered cardiac blood vessels in the first U.S. patients. The implants, which are used to connect a major cardiac vein and the artery that carries blood to the lungs, are made of a synthetic scaffold seeded with cells from the patient's own bone marrow. In the body, the graft develops into a living blood vessel that grows with the patient. But new experiments suggest that inflammation, long seen as an enemy of transplants and artificial implants alike, seems to play a key role in the transformation of the cell-filled scaffold into a healthy blood vessel. And stem cells, which have been seen as the stars of tissue engineering, play a less significant role than expected. The results are prompting tissue engineers to rethink the role of inflammation and stem cells.